Remove channels womens-health
article thumbnail

The biggest waste of digital media spending in pharma

World of DTC Marketing

Pew Internet found that most online health seekers (86%) visit multiple sites when looking for health information and do not have one favorite site. . Eighty-nine percent of health seekers who visit multiple sites say that, in general, they start at a place like Yahoo or the AOL home page.

Doctors 232
article thumbnail

National Association of Specialty Pharmacy (NASP) 2022 Annual Meeting & Expo

Drug Channels

Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Copyright © 2006-2022 Pembroke Consulting, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

National Association of Specialty Pharmacy (NASP) 2021 Annual Meeting & Expo

Drug Channels

We continue to work with federal, state, and local health officials to strictly adhere to current rules and requirements and do everything possible to protect the health and safety of all attendees. Drug Channels, or any of its employees. d/b/a Drug Channels Institute. Register today for this important industry event!

article thumbnail

8 amlodipine alternative drugs for blood pressure

Druggist

Amlodipine is classified as a calcium channel blocker ( CCB ). Calcium channel blockers have a distinct mechanism of action to beta-blockers. . Calcium channel blockers like amlodipine are the first-line treatment in no-diabetic patients over 55 years of age or patients of the Caribbean or African origin (any age).

Drugs 105
article thumbnail

Bayer provides funding to five more digital health start-ups

pharmaphorum

Bayer has provided funding to five more digital health start-ups as part of its G4A partnering programme, which has already provided backing for more than 150 companies since 2013. This year’s competition sought out digital health innovations in four key areas: cardiometabolic and renal disease, oncology, women’s health and pharmacovigilance.

Genome 64
article thumbnail

NICE expands breast cancer patient population eligible for Enhertu

pharmaphorum

The HER2-targeting antibody-drug conjugate (ADC) can be used to treat HER2-positive, unresectable, or metastatic breast cancer after one or more prior anti-HER2 therapies, according to final draft guidance from the health technology assessment (HTA) agency, which is due to come into force on 1 February.

Drugs 64
article thumbnail

Test New Investigational Hearing Devices and Get Paid

Trialfacts

Qualified health professionals will monitor your health as it relates to the study. Men and women aged 18 years old and above who are diagnosed with hearing loss. The Group’s globally diversified sales and distribution channels serve an ever-growing consumer base in more than 100 countries. Who Can Participate?